Implantable medical device developer Tepha said today it completed a buy-out of its roylaty obligations with former licensor and parent company Metabolix. Get the rest of the story at our sister site, Medical Design & Outsourcing
Metabolix
Tepha buys its way out of Metabolix bioresorbables deal
Absorbable biomaterial developer Metabolix said it amended its license agreement with medical device company Tepha, forgoing future royalties and providing 2 additional Metabolix production strains and related IP in exchange for a $2 million lump sum. Read the full story at our sister site, Medical Design & Outsourcing.